Emerging pharmacotherapeutic agents for insomnia: a hypnotic panacea?

Bibliography

• JOHNSON EO, ROTH T, SCHULTZ et al.: Epidemiology of DSM-IV insomnia in adolescence: lifetime prevalence, chronicity, and an emergenbt gender difference. Pediatrics (2006) 117:247-256.
   PubMed Web of Science ®Google Scholar
• DACOURT G, PRINGUEY D, SALLIERE D, LAVOISY J: The safety and tolerability of zolpidem –an update. J. Psychopharmacol. (1999) 13(1):81-93.
   PubMedGoogle Scholar
• ASNIS GM, CHAKRABURTTY A, DUBOFF EA et al.: Zolpidem for persistent insomnia in SSRI-treated depressed patients. J. Clin. Psychiatry (1999) 60(10):668-676.
   PubMed Web of Science ®Google Scholar
• STANER L, ERTLE S, BOEIJINGA P et al.: Next-day residual effects of hypnotics in DSM-IV primary insomnia: a driving simulator study with simultaneous electroencephalogram monitoring. Psychopharmacology (2005) 181:790-798.
   PubMed Web of Science ®Google Scholar
• ROEHRS T et al.: Efficacy and safety of 6.25 mg of zolpidem modified release formulation in elderlypatients with primary insomnia [poster]. Presented at the 158th American Psychiatric Association Meeting. Atlanta, GA (21 – 26 May, 2005).
   Google Scholar
• ELIE R, RUTHER E, FARR I, EMILIEN G, SALINAS E: Sleep latency is shortened during 4 weeks of treatment with zaleplon, a novel nonbenzodiazepine hypnotic. J. Clin. Psychiatry (1999) 60:536-544.
   PubMed Web of Science ®Google Scholar
• KRYSTAL AD, WALSH JK, LASKA E et al.: Sustained efficacy of eszopiclone over 6 months of nightly treatment: results of a randomized, double-blind, placebo-controlled study in adults with chronic insomnia. Sleep (2003) 26(7):793-799.
   PubMed Web of Science ®Google Scholar
• ZAMMIT GK, MCNABB LJ, CARON J, AMATO DA, ROTH T: Efficacy and safety of eszopiclone across 6-weeks of treatment for primary insomnia. Curr. Med. Res. Opin. (2004) 20(12):1979-1991.
   PubMed Web of Science ®Google Scholar
• ROSENBERG R, CARON J, ROTH T, AMATO D: An assessment and safety of eszopiclone in the treatment of transient insomnia in healthy adults. Sleep Med. (2005) 6:15-22.
   PubMed Web of Science ®Google Scholar
• SCHARF M, ERMAN M, ROSENBERG R et al.: A 2-week efficacy and safety study of eszopiclone in elderly patients with primary insomnia. Sleep (2005) 28(6):720-727
   PubMed Web of Science ®Google Scholar
• ROTH T, STUBBS C, WALSH JK.: Ramelteon (TAK-375), a selective MT1/MT2- receptor agonist, reduces latency to persistent sleep in a model of transient insomnia related to a novel sleep environment. Sleep (2005) 28(3):303-307.
   PubMed Web of Science ®Google Scholar
• ERMAN M, SEIDEN D, ZAMMIT G, SAINATI S, ZHANG J: An efficacy, safety, and dose-response study of Ramelteon in patients with chronic primary insomnia. Sleep Medicine (2006) 7:17-24.
   PubMed Web of Science ®Google Scholar
• WALSH JK, ERMAN M, ERWIN CW et al.: Subjective hypnotic efficacy of trazodone and zolpidem in DSM-III-R primary insomnia. Hum. Psychopharmacol. (1998) 13:191-198.
   Web of Science ®Google Scholar
• SALETU-ZYHLARZ GM, ABU-BAKR MH, ANDERER P et al.: Insomnia related to dysthymia: polysomnographic and psychometric comparison with normal controls and acute therapeutic trials with trazodone. Neuropsychobiology (2001) 44:139-149.
   PubMed Web of Science ®Google Scholar
• SALETU-ZYHLARZ GM, ABU-BAKR MH, ANDERER P et al.: Insomnia in depression: differences in objective and subjective sleep and awakening quality to normal controls. Prog. Neuropsychopharmacol. Biol. Psychiatry (2002) 26:249-260.
   PubMed Web of Science ®Google Scholar
• COSTABILE RA, SPEVAK M: Oral trazodone is not effective therapy for erectile dysfunction: a double-blind, placebo controlled trial. J. Urol. (1999) 161:1819-1822.
   PubMed Web of Science ®Google Scholar
• WARNER MD, DORN MR, PEABODY CA: Survey on the usefulness of trazodone in patients with PTSD with insomnia or nightmares. Pharmacopsychiatry (2001) 34:128-131.
   PubMed Web of Science ®Google Scholar
• HAJAK G, RODENBECK A, VODERHOLZER U et al.: Doxepin in the treatment of primary insomnia: a placebo-controlled, double-blind, polysomnographic study. J. Clin. Psychiatry (2001) 62:453-463.
   PubMed Web of Science ®Google Scholar
• WALSH JK, ZAMMIT G, SCHWEITZER PK, ONDRASIK J, ROTH, T: Tiagabine enhances slow wave sleep and sleep maintenance in primary insomnia. Sleep Medicine (2005) xx:1-7.
   Google Scholar
• Indiplon modified-release, Indiplon MR, NBI 34060, NBI 34060 modified release, NBI 34060 MR. Drugs R. D. (2002) 3(3):197-199.
   PubMedGoogle Scholar
• KROGSGAARD-LARSEN P, FROLUND B, LILJEFORS T, EBERT B: GABA A agonists and partial agonists: THIP (Gaboxadol) as a non-opioid analgesic and a novel type of hypnotic. Biochem. Pharmacol. (2004) 68:1573-1580.
   PubMed Web of Science ®Google Scholar
• MATHIAS S, ZIHI J, STEIGER A, LANCEL M: Effect of repeated gaboxadol administration on night sleep and next-day performance in healthy elderly subjects. Neuropsychopharmacology (2005) 30:833-841.
   PubMed Web of Science ®Google Scholar
• FISH LR, GILLIGAN MT, HUMPHRIES AC et al.: 4-Fluorosulfonylpiperidines: Selective 5-HT 2A ligands for the treatment of insomnia. Bioorg. Med. Chem. Lett. (2005) 15:3665-3669.
   PubMedGoogle Scholar
• GLASS J, LANCTOT KL, HERRMANN N et al.: Sedative hypnotics in older people with insomnia: meta-analysis of risks and benefits. Br. Med. J. 331(7526):1169.
   PubMedGoogle Scholar
• PIGEON WR, PERLIS ML: The long-term management of chronic insmonia: recommendations for primary care physicians. Insom. (2005) 5:4-9.
   Google Scholar